Valuation

RVMDREVOLUTION Medicines Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

+8.2% today · +213.3% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 22% of the instruments we score

Trend: among the best of its peers; Quality: among the weakest; priced higher than most peers. No dividend.

REVOLUTION Medicines Inc (RVMD) valuation against sector peers: P/B 17.3, free-cash-flow yield −3.5%, P/S 164.6.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricRVMDSector medianvs median
P/E—29.2 · n=157—
P/B17.33.8 · n=307354% above
P/S164.64.1 · n=3003,935% above
EV/EBIT—25.6 · n=145—
Free-cash-flow yield−3.5%1.5% · n=289334% below
Dividend yield0.00%0.00% · n=362—
Return on equity−93.6%−2.4% · n=306—
Return on invested capital−74.1%0.6% · n=28011,599% below
Gross margin—63.3% · n=205—
Net debt / EBITDA—1.30 · n=150—

Value factor: 18 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co46.231.6—1.5%0.6%6/10
JNJJohnson & Johnson41.38.2—3.1%1.9%8/10
ABBVAbbVie50.0—27.63.7%2.9%6/10
MRKMerck147.58.1—4.1%2.3%8/10
UNHUnitedHealth22.23.416.96.5%2.3%10/10
TMOThermo Fisher Scientific36.44.734.53.0%0.3%9/10
AMGNAmgen26.517.423.03.8%2.2%8/10
GILDGilead Sciences—15.9—6.7%1.9%4/10
ABTAbbott40.53.732.83.5%2.8%6/10
PFEPfizer41.51.9—7.0%7.3%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026